XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Components (Tables)
6 Months Ended
Jun. 30, 2023
Balance Sheet Components [Abstract]  
Schedule of Cash, cash equivalents, and restricted cash
Cash and restricted cash
(In millions)June 30,
2023
December 31,
2022
June 30, 2022
Cash and cash equivalents$629.2 $1,259.9 $664.7 
Restricted cash, included in prepaid expenses and other current assets2.2 2.6 4.7 
Cash, cash equivalents and restricted cash$631.4 $1,262.5 $669.4 
Inventories
Inventories
(In millions)June 30,
2023
December 31,
2022
Raw materials$417.5 $571.5 
Work in process1,132.2 755.4 
Finished goods2,091.8 2,192.6 
Inventories$3,641.5 $3,519.5 
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets
(In millions)June 30,
2023
December 31, 2022
Prepaid expenses$205.8 $194.6 
Deferred consideration due from Biocon Biologics164.8 — 
Available-for-sale fixed income securities35.5 35.3 
Fair value of financial instruments94.6 134.7 
Equity securities46.7 42.6 
Other current assets1,177.7 1,404.0 
Prepaid expenses and other current assets$1,725.1 $1,811.2 
Property, Plant and Equipment
Property, plant and equipment, net
(In millions)June 30,
2023
December 31, 2022
Machinery and equipment$3,011.0 $2,936.7 
Buildings and improvements1,502.8 1,539.7 
Construction in progress407.3 474.0 
Land and improvements125.1 133.4 
Gross property, plant and equipment5,046.2 5,083.8 
Accumulated depreciation2,063.0 2,059.3 
Property, plant and equipment, net$2,983.2 $3,024.5 
Other Assets
Other assets
(In millions)June 30,
2023
December 31, 2022
Non-marketable equity investments$154.2 $94.0 
Deferred consideration due from Biocon Biologics146.1 299.5 
CCPS in Biocon Biologics1,028.9 997.4 
Operating lease right-of-use assets250.4 259.3 
Other long-term assets771.5 753.3 
Other assets$2,351.1 $2,403.5 
Accounts payable
Accounts payable
(In millions)June 30,
2023
December 31, 2022
Trade accounts payable$1,309.6 $1,158.0 
Other payables652.4 608.6 
Accounts payable$1,962.0 $1,766.6 
Other Current Liabilities
Other current liabilities
(In millions)June 30,
2023
December 31, 2022
Accrued sales allowances$880.2 $888.8 
Legal and professional accruals, including litigation accruals252.1 297.2 
Payroll and employee benefit liabilities672.0 746.8 
Contingent consideration63.7 64.4 
Accrued restructuring47.2 95.3 
Accrued interest64.2 80.2 
Fair value of financial instruments98.7 187.0 
Due to Biocon Biologics11.6 22.5 
Operating lease liability85.3 80.6 
Other871.1 978.1 
Other current liabilities$3,046.1 $3,440.9 
Other Noncurrent Liabilities
Other long-term obligations
(In millions)June 30,
2023
December 31, 2022
Employee benefit liabilities$530.5 $544.6 
Contingent consideration (1)
315.4 310.6 
Tax related items, including contingencies393.1 414.6 
Operating lease liability166.9 181.4 
Accrued restructuring60.4 60.4 
Other208.0 244.9 
Other long-term obligations$1,674.3 $1,756.5 
(1)    Balances as of June 30, 2023 and December 31, 2022 include $228.4 million and $221.2 million, respectively, due to Biocon Biologics. Refer to Note 11 Financial Instruments and Risk Management for additional information.